Evolution Global Talent Attraction featured on GEN JobWatch

Evolution founder and Managing Director Dr. Jason Beckwith was recently featured on monthly Genetic Engineering & Biotechnology News column JobWatch. Dr. Beckwith offered GEN an insight into the hiring practices

Share
Sigma-Aldrich Announce Q1 2015 Sales Figures

Sigma-Aldrich Corporation have posted strong Q1 2015 results ahead of their planned merger with Merck later this year. Sigma reported quarterly sales of $676 million, with an organic growth rate

Share
Merck appoints Udit Batra to head combined life science business ahead of Sigma-Aldrich acquisition

Udit Batra has been appointed to lead the combined life science business of Merck Millipore and Sigma-Aldrich once the acquisition of Sigma-Aldrich has been successfully completed later this year. Udit

Share
Scottish CRO BioOutsource Acquired by Sartorius Stedim Biotech

Scottish Contract Research Organisation BioOutsource have been acquired by global biopharmaceutical supplier Sartorius Stedim Biotech (SSB) for an undisclosed amount. The takeover strengthens SSB’s service portfolio throughout the drug development

Share
Sigma-Aldrich Launch New APAC Headquarters and Cell Culture Technical Center

Global Life Science and High Technology company Sigma-Aldrich announced the opening of their new Asia Pacific headquarters and state-of-the-art Cell Culture Technical Center at the Biopolis Research Park in Singapore.

Share
Bio-Rad Reports Strong Fourth-Quarter and Full-Year 2014 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today for the fourth quarter and fiscal year ended

Share
Plant Impact and Bayer CropScience enter multi-year partnership

Plant Impact plc today announced that it has signed an agreement with Bayer CropScience to develop yield enhancing technologies for soy cultivation. The agreement encompasses a multi-year partnership for Plant

Share
Sigma-Aldrich Reports Record Full-Year 2014 Sales

Sigma-Aldrich (NASDAQ – SIAL) Reports Record Full-Year 2014 Sales Of $2.79 Billion And Record Adjusted Diluted EPS Of $4.37. Reports Q4 2014 Adjusted Diluted EPS Of $1.14 And Organic Sales

Share
Merck, Sanofi, Syngenta & GSK announce full year results for 2014

Pharma giants Merck, Sanofi & GSK announced their full-year results for 2014 this week, as did global AgroChemical multinational Syngenta. Syngenta reported sales of $15.1 billion USD, achieving their integrates

Share
Thermo Fisher Strengthens Bioproduction Offering by Acquiring Advanced Scientifics

Thermo Fisher Scientific have announced their acquisition of ASI (Advanced Scientifics, Inc.) for a cash payment of $300 million USD as the company seeks to strengthen their bioproduction offerings. ASI

Share
Teixobactin Discovery Heralded as an Antibiotic Game Changer

Up until now uncultured bacteria have been an untapped source of new antibiotics, but promising research published in Nature yesterday highlights novel in-situ methods for growing uncultured microorganisms. One of

Share
Elsevier to Launch Open Access Multi-Disciplinary Scientific Journal

Academic publishing giant Elsevier have announced the forthcoming launch of a new open access multi-disciplinary scientific journal, calling for researchers to adopt a new collaborative and open source ethos. Dr.

Share
23andMe and Genentech Announce Research Partnership

Controversial DNA sequencing company 23andMe announced the first of 10 deals to be signed with large biotech and pharma firms on Tuesday January 6. Their $60 million partnership with Genentech

Share

BioReliance® Introduces Advanced In Vitro ADME and Toxicology Services Designed to Improve Drug Safety and Efficacy BioReliance® (www.bioreliance.com), Sigma-Aldrich Corporation’s (NASDAQ: SIAL) biologics and early-development services business under SAFC® Commercial

Share

Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry Merck to acquire Sigma-Aldrich for $140 per share in cash, valuing company at approx. $17 billion (€13.1 billion)

Share